Drug archive
Ibritumomab Tiuxetan (Systemic)
Archived drug information. This USP DI monograph is kept for reference and dates from the mid-2000s. Doses, warnings, interactions and brand names may have changed, and some products are no longer sold. Always follow your prescriber, your pharmacist and the current label, for example on DailyMed.
Category
- Monoclonal antibody
- antineoplastic (radioactive)
Description
Ibritumomab Tiuxetan (ib-ri-TU-moe-mab) (tie-ux-EH-tan) is a protein called a monoclonal antibody. It is used along with another monoclonal antibody (rituximab) and two radioactive pharmaceuticals (In-111 and Y-90). Ibritumomab tiuxetan is used to treat a type of cancer called non-Hodgkin's lymphoma.
Ibritumomab Tiuxetan is to be administered only by or under the immediate supervision of your doctor. It is available in the following dosage form:
- Injection (U.S.)
Brand Names
Some commonly used brand names are:
In the U.S. -
- Zevalin
Other commonly used names are:
- IDEC-2B8 (ibritumomab tiuxetan)
- IDEC-Y2B8 (yttrium-90-ibritumomab tiuxetan)
- IDEC-In2B8 (indium-111-ibritumomab tiuxetan)
- IDEC-129
† Not commercially available in Canada.